Clinical Trial Update: Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of inhaled aviptadil acetate (ZYESAMI) for severe COVID-19 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyspnea
• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• Inhaled ZYESAMI (aviptadil acetate)

Snippet

Sponsor: APR Applied Pharma Research s.a. | Conditions: SARS-CoV 2, COVID | Phase 3 | Status: WITHDRAWN